FY 2025 Guidance Unchanged The Company's guidance for FY 2025 under U.S. GAAP is unchanged. Guidance assumes no material change in exchange rates for key currencies compared with FY 2024 average rates, notably USD/GBP and USD/EUR. Guidance also assumes no material change to Medicaid eligibility policy and/or other changes to Federal funding levels due to executive actions. Guidance also does not include any potential impacts from tariffs imposed by the U.S. government or any retaliatory tariffs that may be imposed by other countries. FY 2025 Net Revenue (NR) $955m to $1,025m (-17% at the mid-point vs. FY 2024) SUBLOCADE NR $725m to $765m (-1% at the mid-point vs. FY 2024) OPVEE NR $10m to $15m SUBOXONE Film Market Share Accelerated NR decline in FY 2025 reflecting increased generic competitive activity and the potential impact from a fifth buprenorphine/ naloxone sublingual film generic in the U.S. market Non-GAAP Gross Margin Low to mid-80s % range Non-GAAP SG&A ($525m) to ($535m) Non-GAAP R&D ($85m) to ($90m) Non-GAAP Operating Income $185m to $225m